newsfilter
← Latest News
GlobeNewswire·

Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights

Q1 2026 Vafseo® (vadadustat) net product revenues grew to $15.8 million; Q1 2026 total net product revenues of $52.0 million Number of patients treated with Vafseo increased 60% in Q1 2026 compared to Q4 2025